THE CURRENT STATUS AND PERSPECTIVES FOR THE EMERGING PANDEMIC: COVID-19 by V. B., CHANDANA KUMARI et al.
Ramu et al. 





THE CURRENT STATUS AND PERSPECTIVES FOR THE EMERGING PANDEMIC: COVID-19 
 
CHANDANA KUMARI V. B.a, SHASHANK M. PATILa, PRITHVI S. SHIRAHATTIb, SUJAY S.a, TEJASWINI M.a, 
LAKSHMI V. RANGANATHAc, JAYANTHI M. K.d, RAMITH RAMUa* 
aDepartment of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru 
570015, Karnataka, India, bPost-Graduation Department of Biotechnology, Teresian College, Siddhartha Nagara, Mysuru 570011, India, 
cDepartment of Chemistry, The National Institute of Engineering, Manandavadi Road, Mysuru, Karnataka, 570008, India, dDepartment of 
Pharmacology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India 
Email: ramithramu@jssuni.edu.in 
Received: 07 May 2020, Revised and Accepted: 09 Jun 2020 
ABSTRACT 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the extremely communicable viral infection 
coronavirus disease 19 (covid-19). Initially the virus was found at Wuhan, china which spread across the world exponentially and in a very short 
span. This outbreak has turned out to be a global health crisis and recently WHO regarded it as pandemic. The origin of the virus is predicted as 
either the natural selection in animal host prior to the transfer of the pathogen from animals to humans or the natural selection in humans and 
following transfer. Nevertheless, there is an extensive spread of virus by human to human transfer in the form of droplets. A few antiviral drugs are 
at the stage of clinical trials to eradicate the covid-19. In this review, a comprehensive approach is put forth to scrutinise the etiology, pathogenicity 
and transmission of SARS CoV-2. The review also deliberates broadly on the diagnosis and status of therapeutic treatment developed. It also focuses 
on the preventive and controlling measures from different sectors of the society. The review covers the details reported in 70 studies which were 
chosen after keyword searches carried out leading to over 884 resulting articles.  
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INTRODUCTION 
The world has witnessed an array of contagious outbreaks since time 
immemorial. These outbreaks were caused by a series of bacteria, 
viruses and other pathogens [1]. These outbreaks were either 
epidemic, where a small population or community gets affected for a 
limited duration of timeor pandemic, when the whole world might be 
at risk [2]. Thus, a pandemic is more contagious and dangerous 
compared to an epidemic and emphasized in this review primarily 
due to the misinterpretation of the disease in discussion as epidemic 
at the first mention, which was later declared to be a pandemic [3, 
4]. Covid-19 or commonly known as corona virus disease, is caused 
by a virus, known as Severe Acute Respiratory Syndrome Corona 
Virus (SARS-COV-2) [5]. Owing to the health and economic crisis it has 
created around the globe from a past few months, it can be declared 
that covid-19 is one of the most pernicious outbreaks of all time [6]. 
The history dates to 2003, when China officially reported the first 
outbreak of SARS-CoV-1. It was first spotted in humans in the 
Guangdong province of southern China in 2002 [7]. Another relative 
virus, Middle East Respiratory Syndrome Corona Virus (MERS-CoV), 
was first reported in Arabian Peninsula of Saudi Arabia in 2012 [8]. 
Both virus outbreaks resulted in significant number of deaths around 
the globe. In December 2019, China had a cluster of unidentified cause 
of pneumonia patients in Wuhan, with clinical characteristics 
significantly like viral pneumonia [9, 10]. According to one study, an 
exotic animal market in Wuhan city became the centre of the outbreak 
and there was a rapid increase in the rate of transmission [11]. This 
led to an immediate examination to characterise the cause of the 
disease and was identified to be due to novel coronavirus (nCoV). 
Later, it was named as SARS-CoV-2, by International Committee on 
Taxonomy of Viruses (ICTV) on 11th February 2020 which is also 
called as covid-19 [12]. 
The severity of SARS-CoV-2 is attributed to its life cycle which 
involves potential natural hosts, intermediate hosts and final hosts. 
SARS-CoV-2 has great transmissibility and infection causing ability 
[13] compared to its relative viruses, MERS-CoV and SARS-CoV-1. β-
coronaviruses are a large family of enveloped, diverse-natured, 
positive-sense and possess single stranded RNA. It is reported to 
affect both animals and humans, resulting in neuronal, hepatic, 
gastrointestinal abnormalities chiefly affecting respiratory system 
[14-16]. Both MERS-CoV and SARS-CoV-1 are responsible for highest 
reported mortality rates (10% and 40%) in human beings [5]. Being 
the centre of the pandemic, initially China reported more than 90% 
of the cases and deaths. However, eventually an outbreak of the 
disease was observed in places such as Italy, Spain and USA bringing 
these countries toll on par with that of China. Most of the reported 
cases were associated with symptoms resembling pneumonia, 
including cough, fever, myalgia or fatigue [10]. Up to 23rd April, 
WHO reported 30,90,445 confirmed active cases with 2,17,769 
deaths with India reporting 35,043 active cases with 1,154 deaths. 
According to WHO, the pandemic has spread over 208 counties [17]. 
The review was planned to report the status of covid-19 pandemic, 
including its origin and transmission. As it was designed to highlight 
the available therapeutics, preventive and control measures, a 
systematic search was conducted using two major databases. Both 
Google Scholar and PubMed were used to identify published studies 
related with details about Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome-1 
(SARS-CoV-1), and Severe Acute Respiratory Syndrome-2 (SARS-
CoV-2). It was completed in accordance with the guidelines given by 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA).  
The objectives of the review were planned and independently 
written by all the 8 authors. The corresponding author was engaged 
to resolve the conflicting interest in the article. For the collection of 
published studies, we used the key-words like “SARS-CoV-1”, “Covid-
19”, “SARS-CoV-2”, “Detection”, “Diagnosis”, “Clinical Symptoms”, 
“Infection”, “Transmission”, “Pharmacotherapy”, “Immunotherapy”, 
“Vaccines”, “Prevention” and “Controlling measures”. In this manner, 
individual studies were collected and further screened according to 
relevance to suit the requirement. A total of 884 of studies resulted 
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from our search criteria and were analysed for duplicates and 
relevant content. In the first screening, 23 of the studies were 
removed out of which 19 duplicates and 3 belonged to herbal 
medications. As the study was strictly designed to report current 
pharmacotherapeutic agents, ongoing clinical trials and 
immunotherapeutic agents, herbal medications with no clinical 
proof were discarded. The remaining 861 studies were grouped 
under the planned objectives, in which major selection was carried 
out. Furthermore, individual authors reported the number eligible 
studies as 246. A second and last phase of selection was carried out 
with respect the perspective of the review. Finally, we found only 70 
studies that were able to perfectly fit into the perspective of the 
review article. The scenario of the search identification and selection 
has been depicted in the fig. 1. 
 
 
Fig. 1: Flow diagram of the search strategy Created with "BioRender.com" 
 
Current issues and global scenario 
It was reported that a total of 44 cases of pneumonia patients of 
unknown causal agent, from 31 December 2019 through 3 January 
2020 in Wuhan city. As the cause was known to be a viral infection 
there was confirmed cases of SARS-CoV-2, 278 cases in China, 2 
cases in Thailand and 1 each case in Japan and Republic of Korea by 
20 January 2020 [18]. First case in India was reported on 30 January 
2020, almost 649 cases and 13 deaths were reported by 26 March 
2020 [19]. Covid-19 is extremely infectious disease with an 
estimated R0 values of about 2.28 (2.06-2.52), which indicates SARS-
CoV-2 is in the epidemic phase and has very strong transmission 
capacity [20]. Presently, there are about 3 million cases confirmed 
globally; 1,406,899 infected with 129,311 deaths in European 
region, 1,213,088 confirmed and 62,404 deaths in America, 176,928 
confirmed and 7304 deaths in the Eastern Mediterranean region, 
146,449 confirmed and 6037 deaths in Western Pacific region, 
51,351 confirmed and 2001 deaths in South-East Asia region and 
23,254 confirmed and 903 deaths in Africa as on 29 April 2020 [21]. 
In India, as on 1 May 2020, there are 25007 active cases with 1147 
deaths [22]. 
Origin and evolution of SARS CoV-2 
COVID-19 is also well known as 2019 novel coronavirus, otherwise it 
is also referred as 2019-nCoV. It was first recognised in Wuhan 
China and the World Health Organization declared the coronavirus 
outbreak with an official name covid-19 on 11 February 2020. This 
virus causes the upper-respiratory tract illness, which was not found 
to be infecting humans when first identified [23]. In 1937, corona 
type of virus was first isolated from chickens. Later in the mid-
1960s, human coronaviruses were identified for the first time. 
Coronavirus is a sense-strand RNA virus; single-stranded enveloped 
consisting genome of 30Kb [16]. Based on the Coronaviridae family, 
genera can be divided into four: α, β, γ, and δ. The birds get infected 
usually by γ and δ genera of coronavirus, whereas the humans and 
mammals are infected by α and β genera. The novel Severe Acute 
Respiratory Syndrome coronavirus-2 (SARS-CoV-2) infecting the 
humans are the β-coronavirus that appears as oval or round and 
crown shape when observed under electron microscope [24]. 
Further studies on the genera of coronavirus elucidated that the bats 
usually are the reservoirs of α and β genera while birds carry γ and δ 
genera of coronavirus. The studies also reported the progenies of the 
lineage of β-coronavirus within rhodents [25, 26]. 
SARS-CoV, MERS-CoV, NL63, HKU1, OC43 and 229E are human 
coronavirus, among this SARS CoV-2 is the 7th coronavirus infecting 
humans. Infections by HKU1, OC43, NL63 and 229E cause mild 
symptoms but the SARS-CoV, MERS-CoV and SARS CoV-2 are 
associated with severe symptoms and causes disease [27]. Origin of 
the SARS CoV-2 can have two prospects, firstly its can be predicted 
that natural selection in animal host prior to the transfer of 
pathogen from animals to humans. Secondly, we can predict as the 
natural selection in humans and resulting animal to human transfer. 
Covid-19 cases were reported initially in Huanan market located in 
Wuhan. T, which most likely emerged from the animal source owing 
to its resemblance of SARS CoV-2 to several other coronaviruses. 
The bat seems to be reservoirs of SARS CoV-like coronaviruses, 
which were unable to efficiently invade the humans. The mutations 
in structural covering of spike protein of the virus enabled the access 
to bind the humans with the aid of ACE2 receptors. As per the first 
perspective, the animal host would have allowed the natural 
selection process to effectively cause the necessary changes in order 
 
to escape its host and dwell within the human hosts
possibility as per the second perspective, that the progenies of SARS 
CoV-2 hurdled into humans and adapted inits genomic 
characteristics and then spread the infection rapidly 
to human transfer [28]. 
Infection and transmission  
Mode of transmission 
The phylogenetic analysis and the protein sequencing from 
19 virus exhibited similarity with ACE2 receptors in turtles and 
pangolins which are genetically closer to humans and bat. It is 
suspected that these species can be an alternate intervening hosts 
transmitting SARS CoV-2 to human [29]. T
 
Fig. 2: Mode of transmission of 
Mode of infection 
Structurally, the outermost layer SARS CoV-
made up of glycoprotein on the surface that helps the virus to invade 
host cells [34]. The S protein which is recognised by the host ACE2
receptor initiates the virus life cycle in host cell through endocytosis. 
The endosomal pathway fusion takes place between the viral 
envelope and the host cell membrane with the release of viral 
nucleocapsid into the cytoplasm. The RNA of SARS
which gets translated to polyproteins pp1a and 1ab (viral replicase). 
 
Fig. 3: Mode of infection of 
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. There is also a 
through human 
COVID-
he virus can be 
transmitted through droplets of saliva
either from short or long distance by talking, breathing
and coughing respectively [30]
transmission through droplets within 1m 
or sneeze and the pathogen can 
mouth, nose and eyes. The objects or materials which encountered 
the infected person or the environment surrounding can also 
transmit the infection of virus 
droplet mostly reflected as a particle and it can
transmission [32]. Consumption of milk from an infected animal and 
urine of the animal may also contain virus. The undercooked or 
uncooked meat consumed directly were also theorised to be main 
course of transmission [33]. The mode of transmission from primary 
host to humans has been depicted in 
Covid-19 [13] Created with "BioRender.com"
 
2 consists of spikes 
 
-CoV-2 is released, 
Later, the viral proteinase cleaves the RNA replicase to smaller 
fragments which persuade the structural rearrangements in the cell 
membrane to form double-membrane vesicles (DMVs). A chain of 
sub genomic mRNAs is produced by polymerase
of discontinuous transcription and the viral proteins are translated 
pertinently. The combination of viral proteins and RNA genome 
successively accumulate to form a virion in ER
complex (ERGIC). Finally, through secretory pathway, the mature 
virions are transported and released out of the cell in smooth
vesicles as shown in the fig. 3 [13, 35]
Covid-19 [35] Created with "BioRender.com"
8, 1-10 
3 
, nose discharge and aerosols 
, sneezing 
. The person infected can cause 
proximity either by cough 
enter the healthy person through 
[31]. The virus is present within the 
not be an airborne 
fig. 2. [13]. 
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Symptoms of infection 
Incubation period for covid-19 is 14 d and within 4-5 d one can 
observe the onset of symptoms. SARS-CoV-2 infection would 
develop symptoms within 11.5 d in the infected person and although 
vary between individuals at the onset, most common symptoms are 
fever, cough, tiredness, eating disorder or also known as anorexia, 
shortness of breath, excess of sputum production and muscle pain 
[36]. Least commonly reported symptoms are headache, 
disorientation, mucus fluid secretions in nasal cavity, sore throat, 
mucus containing blood stains from the bronchi, larynx, trachea, or 
lungs, vomiting, and diarrhea [10, 11, 37, 38]. In certain cases, 
patients also exhibit other common symptoms rarely such as pain in 
the abdominal region, abdominal distension and recurrent 
inclination to evacuate the bowels [39]. According to patient’s 
analysis nausea, vomiting and diarrhea appear at variable 
percentages [40]. The patients admitted initially of heart palpitation 
and chest tightness were also found to be infected with covid-19. 
The patients associated with cardiovascular disease will have high 
secretion of ACE2 compared to a healthy person and therefore more 
prone to developing symptoms of infection. The patient infected 
with SARS CoV-2 with comorbidities such hypertension or diabetes 
mellitus are in extreme danger. It is recommended that greater care 
should be taken of people suffering from cardiovascular diseases, 
hypertension and diabetes mellitus to not encounter COVID-19 
positive people [41, 42]. Lately, with close observation of patients 
infected with COVID-19 also exhibited loss of smell that is anosmia, 
associated with or without parageusia means confusion of the sense 
of taste [43]. There are also possibility of asymptomatic infections 
and the transmission of SARS CoV-2, although confirmed yet [44]. 
 





Mechanism of action Original 
indication 
Dosage information References 
Hydroxychloroquine/C
hloroquine 
Off-label use for 
anti-viral 
treatment 
Increases intracellular pH in host 
cells, thus inhibiting RNA synthesis. 
Facilitates the glycosylation 
impairment of ACE2, by disrupting 
viral S protein thereby preventing 
the entry of SARS-COV-2 into the host 
cell. Also known to possess anti-
inflammatory and 






400 mg on first day 
followed by 200 mg 
for four days, twice, 
orally. 
Chloroquine: 500 mg 
twice for 5 d, orally. 
Barlow et al. 
2020; Tu et al. 
2020; McCreary et 
al. 2020 [53-55]. 
Remdesivir Off-label use for 
anti-viral 
treatment  
Guanosine nucleoside that 
specifically inhibits viral RNA 




200 mg on first day, 
followed by 100 mg 
for up to 10 d 
intravenously 
Barlow et al. 
2020; Tu et al. 
2020; McCreary et 
al. 2020 [53-55] 
Lopinavir and 
Ritonavir  
Off-label use for 
HIV-1 treatment 
Acts as an aspartic acid protease 
inhibitor that inhibits viral 
replication hence its life cycle 
HIV-1 200 mg-100 mg for 
14 d through oral 
consumption 
Barlow et al. 
2020; Tu et al. 
2020; McCreary et 
al. 2020 [53-55]. 
Ribavirin Off-label use for 
anti-viral 
treatment  
Nucleoside analog that specifically 
inhibits viral RNA replication using 




400 mg for 14 d, 
twice a day 
Barlow et al. 
2020; Tu et al. 
2020; McCreary et 
al. 2020 [53-55] 
Nitazoxanide Off-label use for 
anti-protozoal 
treatment  
Inhibits hemagglutinin formation 
hence interferes with viral life cycle. 
It may also act on the electron 
transfer activity of pyruvate 
ferredoxinoxidoreductase enzyme, 
thus interfering in the protozoan 
energy metabolism. 
Diarrhea Doses recommended 
for SARS were based 
on age groups; 1-3-
year olds were 
recommended with 
100 mg, 4-11 y with 
200 mg, above 12 y 
with 300 mg for 5 d, 
orally. 
Barlow et al. 
2020; McCreary et 
al. 2020 [53-55]. 
Nelfinavir Off-label use for 
HIV-1 and anti-
viral treatment 
Drug binds to the active site of HIV-1 
protease enzyme and inhibits the 
cleavage of precursors of Gag-Pol 
polyproteinchain, that are essential 
for the survival of HIV-1 inside the 
host. The residues left after the 
molecular process are no longer 
infectious.  
HIV-1 Unknown Barlow et al. 
2020; Shetty et al. 
2020; McCreary et 
al. 2020 [54-56]. 
Favipiravir Off-label use for 
anti-viral 
treatment 
It structurally resembles guanine, 
and through competitive inhibition, 
reduces the efficacy of viral 
replication like remdesivir 
Influenza Unknown Tu et al. 2020; 
Shetty et al. 2020 
[53, 56]. 
Ivermectin Off-label use for 
HIV-1 and anti-
viral treatment 
It can dissociate the preformed IMPα. 
β1 heterodimer, which aids in the 
protein displacement. As the protein 
displacement is essential for the 
maintenance of viral replication, 
targeting the protein displacement 
across the host cell would be a 




Unknown Tu et al. 2020 
[53]. 
Nafamostat Off‑label use for 
anti‑viral 
treatment 
Acts as a serine protease inhibitor, 
inhibits TMPRSS2 associated fusion 
process, may prevent the entry of 
Pancreatitis Unknown Shetty et al. 2020 
[56]. 
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SARS-CoV-2 into host cells. 
Oseltamivir Off‑label use for 
anti‑viral 
treatment 
Neuraminidase enzyme inhibitor that 
may prevent the entry of the virus 
into host cells. Also reduces shedding 
and infectivity of the virus 
Influenza 75 mg  Shetty et al. 2020 
[56]. 
Sofosbuvir Off‑label use for 
anti‑viral 
treatment 
Nucleoside analog that specifically 
inhibits viral RNA replication using 
molecular mimicry mechanism 
Hepatitis-C Unknown Shetty et al. 
2020[56]. 
Zanamivir Off‑label use for 
anti‑viral 
treatment 
Neuraminidase enzyme inhibitor that 
may prevent the entry of the virus 
into host cells. Also reduces shedding 
and infectivity of the virus 
Influenza Unknown Shetty et al. 2020 
[56]. 
Azithromycin Antibiotic The drug acts as an anti-bacterial 
agent and inhibits bacterial infection, 
may possess anti-viral properties.  
Bacterial 
Infections 
500 mg on first day 
followed by 250 mg 
for four days 
Shetty et al. 
2020[56]. 
Emodin Anti-viral drug 
under 
investigation 
Disrupting viral S protein thereby 
preventing the entry of SARS-COV-2 











The drug targets hemagglutinin, a 
glycoprotein present on the surface 
of the influenza virus. It prevents the 
fusion of viral membrane with 





Unknown Tu et al. 2020; 
McCreary et al. 
2020 [53, 55]. 
 










Anti-interleukin (IL)-6 Against Acute 
respiratory distress 
syndrome 
IL-6 can bind to its IL-6 receptor and 
alternative mRNA splicing. Increased IL-6 
content results in reduced lung elasticity 
and increased bronchoalveolar 
inflammation. Inhibiting IL-6 may hamper 





Unknown Tu et al. 2020 
[53]. 
TNF-α inhibitors Anti-inflammatory Reduces lung inflammation caused by 
Tumor Necrosis Factor-α. Blocking these 







 Tu et al. 2020 
[53]. 
Methylprednisolone Anti-inflammatory  Consumption would suppress the 
unwanted immune reactions  
Arthritis, Blood 
disorders 




Through molecular mimicry, it binds to 
sphingosine-1-phosphate (S1P1) 
receptors to reduce the T-lymphocytes in 





Unknown Tu et al. 2020 
[53]. 
Tocilizumab Off-label use to 
hamper unwanted 
immune response 
Monoclonal antibody that binds to IL-6 
receptors to block IL-6 pathway 
Rheumatoid 
Arthritis 
Unknown Tu et al. 2020 
[53]. 
NK-Cells Boosting Anti-Viral 
Response 
Increases the number of cytokines and 
chemokines, without the help of CD8+and 
antibodies. Migration towards viral site 
reduces viral activity.  




Anti-inflammatory  Anti-C5a treatment could reduce lung 
injury by reducing vascular leakage and 
influx of neutrophils into the damaged 
site.  




Anti-viral response  Antibodies present in the sera from 




Unknown Shetty et al. 2020; 
McCreary et al. 




Along with the reduction of TNF-α, it 
reduces multiple inflammatory conditions 












Boosts immune system by attenuating the 
proliferation of inflammatory cells, 
inhibition of phagocytosis, and interfering 






500 mg for 
5 d 





Anti-viral Recovered from patients of COVID-19, 
these antibodies would significantly 
reduce the viral infection 
SARS-CoV-2 Unknown Tu et al. 2020 
[53]. 
Table 3: Available cellular therapeutic agents against covid-19 
Ramu et al. 














Anti-inflammatory Boost immune system by 
supressing inflammatory cells 
and pro-inflammatory 
cytokines. Produce paracrine 
factors to aid tissue repairs.  
SARS-CoV-2 Unknown Golchin et al. 
2020 [57]. 
CAR T Cells Anti-viral activity Specifically binds to the surface 
antigen present on the virus 
and inhibits the viral 
replication inside the host 
Cancer, Hepatitis-
B, HIV-1 
Unknown Bachanova et al. 
2020 [58]. 
 
Table 4: Ongoing vaccine developments against COVID-19 
Company/Institution Estimated timeline Technology Stage/Funding References 
Moderna 
Therapeutics—US 
National Institute of 
Allergy and Infectious 
Diseases 
3 mo to early stage (phase 
1) clinical trial in US 
(earliest); much longer for 
full testing and regulatory 
approval 
Messenger RNA vaccine Preclinical Awaiting 
preclinical tests and 
phase 1 study by NIAID, 
Funding by CEPI. 
Pang et al. 2020 [52]. 
Inovio 
Pharmaceuticals 
Human testing in the next 
few months 
INO-4800-DNA based vaccine (DNA 
synthesized in lab, does not require 
actual virus sample) 
Preclinical Funding by 
Coalition for Epidemic 
Preparedness 
Innovations (CEPI), up 
to $9 million 
Pang et al. 2020 [52]. 
Novavax 3 mo Nanoparticle vaccine Preclinical Pang et al. 2020 [52]. 
University of 
Queensland 
6 mo Rapid Response Technology, 
‘Molecular clamp’ vaccine platform 
(gene added to viral proteins, misleads 
body to generate antibodies) 
Preclinical Funding by 
Coalition for Epidemic 
Preparedness 
Innovations (CEPI) 
Pang et al. 2020 [52]. 
Vir Biotechnology Not available Anti-coronavirus monoclonal 
antibodies. Additionally, using “whole-
genome CRISPR based screening 
capabilities to identify the host 
receptor for Wuhan coronavirus” 
Preclinical Pang et al. 2020 [52]. 
Chinese Centre for 
Disease Control and 
Prevention (CDC) 
At least 1 mo for 
development, 2–3 y 
before availability for use 
Not available Inactivated virus vaccine 










<40 d for manufacture of 
vaccine samples 
mRNA technology Preclinical Pang et al. 2020 [52]. 
Johnson and Johnson 1 y to market Adenovirus—vectored technology 
used for Ebola vaccine (and Zika and 
HIV vaccine candidates)  
Preclinical Pang et al. 2020 [52]. 
University of Hong 
Kong 
Months for animal testing, 
At least 1 y for clinical 
trials on humans 
Modified nasal spray influenza vaccine 
(with surface antigen of coronavirus) 








Target for animal testing 
in 6–8 w, human trials in 
at least a year 
Not available Preclinical Pang et al. 2020 [52]. 
GeoVax—BravoVax Not available Modified Vaccina Ankara—Virus Like 
Particles (MVA-VLP) vaccine platform 
Preclinical Pang et al. 2020 [52]. 
Clover 
Biopharmaceuticals 
Not available Highly purified recombinant 2019-
nCoV S protein subunit-trimer vaccine 
(S-Trimer), produced using Trimer-
Tag© technology 
Preclinical Pang et al. 2020 [52]. 
CureVac Not available mRNA technology Preclinical Pang et al. 2020 [52]. 
Texas Children’s 
Hospital Center for 
Vaccine Development 
at Baylor College of 
Medicine 
Not available Not available Not available Pang et al. 2020 [52]. 
Codagenix Not available Not available Not available Pang et al. 2020 [52]. 
 
Detection and diagnosis 
After the outbreak of COVID-19 in Wuhan(China), WHO has 
recommended that samples should be taken from suspects of SARS-
CoV-2 of respiratory tract specimens like bronchoalveolar lavage 
fluid, pharyngeal and nasal swabs which are subjected to nucleic 
acid amplification diagnostic test, RT-PCR assay and specific method 
to identify patients with respiratory pathogens/infection [45]. To 
detect the infected cases of covid-19, molecular-based approaches 
(Nucleic acid test) are important. Other techniques like serological 
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antibody test are also used, which takes shorter time to detect the 
infection [46, 47]. RT-PCR and next-generation sequencing 
techniques are used to check for the presence of SARS-CoV-2 in the 
specimens of respiratory tract, which are time consuming but far 
more sensitive and efficient. Sequencing of genome is performed to 
design primers and probes that are specific to detect SARS-CoV-2. 
Viral RNA extract of COVID-19 is used as positive control in all 
assays. In real time RT-PCR assay primers and probes that 
specifically target gene of SARS-CoV-2 is used. For SARS-CoV-2 
identification, open reading frames (ORF 1a and 1b), RNA-
dependent RNA polymerase gene (RdRp), envelope (E), and 
nucleocapsid(N) are key sequences for diagnose [17]. 
Advancements in therapeutics treating Covid-19 
One must accept with anguish that there is no specific treatment 
option found to treat COVID-19 till date [5, 48]. All the therapeutics 
now used to treat COVID-19 were once used to treat similar viruses 
named SARS-CoV or MERS-CoV, the outbreaks reported in 2003 and 
2012, respectively [49]. Although they possess an array of working 
mechanisms, these drugs are not ‘specifically’ designed for the said 
infection [48]. Medical professionals are using these drugs either 
separately or in combination for specific duration. In the following 
sections, we have briefly discussed about the ongoing therapeutics 
for covid-19.  
The first and important step that comes into light in case of viral or 
any infectious disease is to be away from the infected person or 
patients termed as social distancing. covid-19 is highly infectious 
and can enter the host through aerosols, just like tuberculosis [50, 
51]. Therefore, it becomes essential to maintain adequate isolation 
to control the viral transmission. Care should be taken that even 
mild symptoms should be reported to medical professionals, so that 
further transmission can be prevented from confirmed patients. The 
medical treatment involves usage of pharmacotherapy, 
immunotherapy, cell therapy and vaccines [52-54]. Tables 1-4 
briefly depict the details of all the therapeutics currently being used. 
Apart from pharmacotherapy and other modes of treating covid-19, 
there is no available vaccine against the pandemic. Though it takes 
significant time to develop vaccines many of the firms and 
institutions have joined hands for the development of vaccines 
against COVID-19 [52, 53]. They are working around the globe to 
ensure that they explore every part of the virus characteristics. It 
should be taken care that cross-contaminations of other vaccines can 
occur, and the effect may be even worse than covid-19 [59]. 
Preventive and control measures 
Every health malady outbreak results in the initiation of preventive 
measures at different levels inside a region, apart from the 
medications. Following these preventive measures would help in 
saving lives, hence would maintain the population levels at constant 
rate [50]. In case of COVID-19, as no specific medications are 
available, prevention would be the best opportunity to survive 
against this global pandemic [50]. The preventive measures can be 
followed in 3 levels including personal level, community level and 
population level. Laws should be made to facilitate the strict 
implementation of preventive measures at every level.  
Role of individuals in the prevention of covid-19 
The transmission of COVID-19 occurs through the exchange of 
aerosols when a healthy individual receives them from a sick person 
[60]. As it belongs to the category of severe acute respiratory 
syndrome (SARS), the highest viral content is possessed by the sputum 
and upper airway secretions [60]. The virus can even remain for days 
on the surface and can result in further complications [10]. Thus, it 
becomes important to wear a fluid resistant (Type-IIR) personal 
protective equipment (PPE) masks to avoid the entry of the aerosols 
and to maintain at-least a two-metre limit on contact. These masks 
should be used by both patients and healthcare professionals to avoid 
further spreading of the virus [61]. FFP2, FF3 and N95 are the types of 
high filtering masks that are usually referred to use against droplets. 
The WHO recommends the use of undamaged FFP2/3 and N95 masks 
for up to 4 h, as it is a median healthcare tolerance time for healthcare 
workers [51]. It is also recommended that regular washing of hands 
should be done with soap, disinfectant or sanitizer with minimum 
60% alcohol in it. Touching of nose, mouth and eyes should be avoided 
with unwashed hands [48]. 
Apart from protecting the body from the external aspects, it also 
becomes vital to maintain the health from internal side. It is 
reported that the western diet mainly comprises of saturated fatty 
acids, refined carbohydrates and fats, leads to the chronic activation 
of innate immune system and attenuation of the adaptive immune 
system [62]. It activates macrophages, neutrophils and dendritic 
cells, thus triggering activation of pro-inflammatory mediators. Also, 
consumption of high fat diet leads to B and T lymphocyte 
inactivation, macrophage infiltration to lungs which in turn leads to 
lung or possible neuro-inflammatory conditions [62]. On the other 
hand, obese people with a habit of high consumption of fats showed 
less response to COVID-19 vaccines [62]. In sum, it is important to 
consider the effects of our daily food and lifestyle on the 
susceptibility to COVID-19 infection. Therefore, it is recommended 
that individuals must shift their diet plans to high amounts of fiber, 
unsaturated fats, antioxidants and whole grains from eating 
unhealthy refined carbohydrates and saturated fatty acids [62]. 
In addition to this, one must look after the safety protocols in clinics 
and hospitals. Room ventilation is believed to clear most of the viral 
aerosols (63%). After 2 exchanges, the viral load reduces in to 14% 
and after 5th exchange, <1%, which becomes an optimum 
environment for the patients [51]. Thus, it also becomes important 
to maintain regular room ventilation protocols. Apart from 
ventilation, it also becomes essential to maintain protocols to avoid 
cross-infection, through the only available way, that is PPE. 
Avoidance of patients, staff or visitors exposed to the virus, repeated 
handwashing, isolation of patients, cleaning the equipment regularly 
and proper disposal of PPE can help in the effective prevention of 
covid-19 transmission [48, 51]. 
Role of society in the prevention of covid-19 
Along with personal efforts to stay away from the pandemic, efforts 
from other two levels, i.e., community and population are also 
essential. In the middle of the pandemic without availability of 
proper and specific therapeutic options, social distancing and 
quarantine prove efficient options to control the further spreading of 
the disease [63]. Social distancing refers to the maintenance of safe 
distance from individuals during interactions in public places like 
utility stores, hotels, theatres etc [64]. While quarantine can be 
defined as the restriction on infected persons in an isolated place 
from the public [63]. It is one of the most misunderstood and feared 
methods of controlling covid-19, because it may affect both infected 
and non-infected individuals with psychological, economical, and 
emotional complications such as post-traumatic stress disorder, 
depression, insomnia, mood swings etc [65]. From the economical 
point of view, quarantine reduces the productivity, hence 
minimalizes the economic growth [66]. According one study, the 
restrictions on travelling and traffic significantly reduced the 
transmission of the virus. Another study showed that quarantine 
strategies are more effective than traffic restrictions. According to 
them, it is estimated to reduce the number of cases by 89.7% [50]. 
Similarly, the idea of city lockdown was proved to be effective when 
a study reported 72% drop in the number of infected people. They 
also suggested that, postponing lockdown would worsen the 
situation by 5 times [50]. Owing to these factors, it becomes clear 
that quarantine can be the best self-preventive method that can be 
practiced at community and national level. 
Contribution of pharmacy and healthline services 
Being in the front line against the pandemic, a lot can be expected 
from the pharmacy and healthline services. Preventive and control 
measures can be at their best with the combination of quarantine 
and activity of healthline services [67]. The pharmacists can develop 
guidance for providing pharmacy services, where researchers across 
the globe, epidemiologists and clinicians can share their views and 
studies on the virus’ characters and controlling methods [68]. This 
hub can result in the development of preventive and control 
methods. Also, on the other hand, pharmacists can put forward their 
formulary manuals and medicine news. Through this approach, 
Ramu et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 8, 1-10 
8 
 
dosage, uses, ingredients and precautions about covid-19 
therapeutics can be made available for the public [68]. Conducting 
drug-based research and evaluation of the drugs can also help the 
nation to look forward to developing new ways to fight the 
pandemic [68]. Establishment of digital platforms to create 
awareness about the pharmacotherapeutic approaches can help the 
people to overcome their misbelieves and confusions about the 
pandemic and its treatment. This system can be the best method in 
situations like city lockdown and quarantine [68]. 
With respect to the healthline services, doctors and medical staff 
should provide their best service to treat the infected as well as to 
create awareness, among others [69]. Specialists and trained staff 
are the two most important necessities in battling covid-19. 
Providing individual care, enough time, facilities to patients can 
result in quick recovery from the disease [69]. Along with this, 
opening medical helplines, telecommunication for remote areas to 
provide information about available treatment information and 
preventive measures would be helpful [68]. It would be better if 
mobile health services get into the front, edifying as well as 
providing medical assistance. This would be considered as a better 
option in conditions like lock-down. Fig. 5 depicts the role of 
pharmacy and healthline in the prevention of covid-19. 
Essentialities in research and development  
Owing to the considerable impact of ongoing covid-19 pandemic on 
health security and global economy, one of the major problems 
raised was inadequate diagnostic and medical equipment, including 
test kits, face masks, sanitizers and therapeutic drugs [69]. It has 
now become necessary for scientists to standardize and develop the 
diagnostic test strips and enzyme linked immunosorbent assay 
(ELISA) kits as additional procurement [70]. Computational 
biological tools and bio-informatics analysis of covid-19 can be the 
resourceful keys to develop the molecular imaging of structural 
proteins and possible mutations [70]. The detection of possible 
reservoir and carriers of the virus can be done with serological 
surveys of suspected animals. This would surely help in the 
controlling the pandemic [70]. On the other hand, it is still essential 
to consider factors like temperature, UV, humidity, behaviour of 
aerosols and biophysical evaluation of all these factors for the 
effective study of covid-19, thus finding a pavement for its 
permanent cure [70]. 
CONCLUSION 
The covid-19 pandemic has been the most dreadful disease in the 
history so far, accounting for loss of millions of lives. It has also 
resulted in the complete halt of importing and exporting essential 
things across the worlds, thus has impaired the global economy. The 
similarity of the virus with the already known viruses is considered 
because of the therapies working on it. Compared to the other 
viruses from the same family, it appears that covid-19 has been 
evolved to withstand all those therapeutics once effective against 
MERS-CoV and SARS-CoV-1. The ongoing therapeutics are used as a 
combination to reduce the viral load in patients, as no specific drug 
is available and many of them are yet to clear the clinical trials, 
including vaccines. 
Though it possesses symptoms like pneumonia, it is lethal and highly 
contagious. Thus, it becomes utmost important to maintain the social 
distancing through lockdown. As no specific drug available, it is better 
to avoid the exposure by maintaining social distancing. Every citizen of 
the country must play his/her role in the prevention and control of the 
pandemic. It is recommended that both lock-down would result in 
significant decrease of mortality rate. The pharmacy and healthcare 
services are already doing their best to fight the pandemic. To boost up 
the efforts, one health approach is recommended. Along with the good 
practices, effective treatment, development of quick and precise 
diagnosing kits, ample production and distribution of PPE can reduce 
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